A prestigious Cancer Moonshot grant from the National Cancer Institute’s Immuno-Oncology Translational Network will enable investigators to explore the mechanisms that allow slow-growing lung cancer lesions to progress into aggressive malignancies and identify new therapeutic strategies to intercept the transition.
Weill Cornell Medicine researchers have shown that giving mice with triple-negative breast cancer therapeutic microRNA (miRNA) in a protective gold nanoparticle results in significantly less spreading of cancer to the lung.
Treating early-stage lung cancers with drugs that unleash the immune system’s ability to attack malignant cells may hinder tumor growth and improve overall survival, according to new research by Weill Cornell Medicine and NewYork-Presbyterian investigators.